Accendatech focuses on discovery and development of "First-in-class" drugs targeting cancer stem cells(CSC). Metastases and relapse are the cause of 90% of human cancer deaths, and CSC plays a key role in the initiation, resistance, relapse and metastasis of many types of cancer, the tumorigenesis capability some CSCs are over 1000 times of that of regular cancer cells. Targeting CSCs holds hope to significantly prevent the relapse and metastasis of many types of cancers, however, it is very difficult to selectively ablate the CSCs, since CSCs have multiple resistance mechanisms, and up to date, the types of natural products targeting CSCs are very limited. Accendatech is one of pioneer bio-companies on R&D of anti-CSCs drugs, based on our understanding of structural and mechanism characteristic of compounds targeting CSCs, our screening platform successfully provides dozens of natural products scaffolds, which may reduce the population of CSCs with selectivity up to 30 folds, and our medicinal chemistry platform efficiently improve the druggability of those natural products. We have establish pipelines with the indications of targeting glioblastoma(GBM), acute myeloid leukemia(AML) and pancreatic cancer. Our first product in clinical trial is ACT001, it can selectively ablate the CSCs in GBM and AML cells, and the concentration of ACT001 in brain is higher than that in blood. In Sept. 2016, clinical trial of ACT001 in Australia started to enroll recurrent brain tumor patients with no standard treatment options. Based on the preliminary results in human, ACT001 was issued the orphan drug designation by FDA in Sept. 2017, and the phase I result was disclosed in this May 16th in ASCO abstract web site: http://abstracts.asco.org/214/AbstView_214_226097.html. The conclusion is following: At well-tolerated doses, ACT001 showed satisfactory bioavailability and preliminary evidence of anti-tumor activity in a subset of patients. The best responses to ACT001 was a partial response in 1 GBM patient (ongoing after 10+ months of treatment). Since the best GBM drug in market(TMZ) can only extend the OS by 2.5 months, our preliminary results of ACT001 as a second line therapy for GBM is very promising, and warrant further investigation with a global phase II trial. Moreover, in the near future, we will also initiate the clinical trial for pediatric DIPG (diffuse intrinsic pontine glioma), a highly deadly brainstem glioma with no approved drugs. If we successfully launch ACT001 into market as a pediatric orphan drug, we will apply for the PRV(priority review voucher) from FDA. The revenue of drug sales and transfer of PRV may support our further investigation of ACT001 in other brain tumors, including the commonly observed intracranial metastatic tumors in lung cancer and breast cancer patients.